Skip to Content
Stock Analyst Update

Which Stocks Will Benefit from Cannabis' Landslide Win?

Every ballot measure was approved.

Mentioned: , , , , , , , , ,

Days after election day, who will be the U.S. president for the next four years remains to be determined as votes continue to be counted. In stark contrast to the fate of the country’s highest office, cannabis won by a landslide in state referendums. Every ballot measure was approved, as Arizona, Montana, and New Jersey expanded legalization to recreational cannabis, Mississippi legalized medical cannabis, and South Dakota shockingly approved both medical and recreational cannabis in one day. Even Oregon’s votes on legalizing psilocybin and decriminalizing all drugs were approved. We view the success on all votes as evidence of still-growing acceptance for legalization among Americans. It also confirms our long-term view for nearly 25% average annual growth for the U.S. recreational market and nearly 15% for the medical market through 2030.

Amongst our coverage, 4-star Curaleaf (CURLF), 3-star Green Thumb (GTBIF), and 4-star Canopy Growth (CGC) immediately benefit from the election outcome. While Canopy only operates in Canada, its standing agreement to acquire U.S. multistate operator, Acreage Holdings, upon a change in federal law gives it economic exposure to Tuesday’s outcome. All three companies already operate in medical cannabis in New Jersey, while Curaleaf also operates in Arizona. When previous states have legalized recreational cannabis, existing medical cannabis operations were entrenched to benefit immediately. 

Three-star Cronos (CRON), 3-star Tilray (TLRY), and 5-star Aurora (ACB) have some exposure to the U.S. but only through hemp-derived CBD. As a result, Tuesday’s outcome will have no direct impact. Despite its announcement the day after the election to acquire U.S. craft brewer Sweetwater, 5-star Aphria (APHA) will also see no direct impact.

 

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Kristoffer Inton does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.